Insight

What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC

Logo of FDA from Dreamstime.com

Aug 21, 2024, 17:08

What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC

On August 19, 2024, the FDA approved a new combination therapy for advanced non-small cell lung cancer (NSCLC). Lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant), both from Janssen Biotech, Inc., can now be used together as a first-line treatment for patients with locally advanced or metastatic NSCLC who have specific genetic mutations, like EGFR exon 19 deletions or exon 21 L858R substitutions, as detected by an FDA-approved test.

Ishwaria Subbiah shared on LinkedIn:

“Started the day with an FDA oncology approval — lazertinib + amivantamab-vmjw for non-small lung cancer!

Perfect time to get ready with the supportive care symptom management plan for our patients!
The most common adverse reactions (≥20%) were rash, nail toxicity, musculoskeletal pain, edema, stomatitis, paresthesia, fatigue, diarrhea, constipation, dry skin, decreased appetite, pruritus, and nausea. “

“Amivantamab plus Lazertinib has received approval as a first-line therapy for EGFR mutated NSCLC, following the Mariposa trial. It’s important to note that this combination is reported to be more toxic, with no observed overall survival benefit as of now. The question remains: Will you change your practice? For many, the answer may be no. However, there could be considerations for specific selective cases. “

Ishwaria Subbiah is the Executive Director for Cancer Care Equity and Professional Wellness at Sarah Cannon Research Institute (SCRI). She is also the medical director of supportive care oncology, health equity and professional well being at The US Oncology Network. Dr. Subbiah focuses on reducing cancer outcomes disparities and diversifying clinical trial participation within SCRI’s combined research network of over more than 1,300 physicians at over 250 locations in 24 states across the US.

Dr. Subbiah is a globally recognized expert in geriatric oncology, symptom management, palliative care, and healthcare professional well-being. She previously was an associate professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. She is the Chair for the ASCO Women in Oncology working group and the ASCO State of Cancer Care in America initiative.

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors.

He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.